Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

As the year draws to an end, Oxford University Press has named the word of the year: rizz. Coined by Gen-Z, rizz means charisma, style and charm. Here is all you need to know about the word that has taken over the internet. Read on!

'Rizz' gets selected as the Word of the Year 2023 by Oxford University Press; here is what it means

As the year draws to an end, Oxford University Press has named the word of the year: rizz. Coined by Gen-Z, rizz means charisma, style and charm. Here is all you need to know about the word that has taken over the internet. Read on!

Oxford University Press has named 'Rizz' as the word of the year 2023! Last year the word of the year was 'Goblin Mode', and this year it is rizz. The term is commonly used by Generation Z (Gen-Z) and means 'style, charm and charisma'. Let us delve deeper into it.
Word of the year: Rizz
Rizz is believed to come from the word charisma and can also be used as a verb like 'rizz up'. &ldquo;Rizz is a term that has boomed on social media and speaks to how language that enjoys intense popularity and currency within particular social communities&mdash;and even in some cases lose their popularity and become pass&eacute;&mdash;can bleed into the mainstream,&rdquo; Casper Grathwohl, President of Oxford Languages said in a statement.&nbsp;
The origin of rizz
The origin of the word can be traced back to Twitch streamer Kai Cenat, who is credited with popularising it on the interactive live-streaming platform. He claimed that he and his friends coined the term that later got popular. He however claims that rizz means 'game' not 'charisma'
Other words that competed were Swiftie, de-influencing, beige flag, rizz, heat dome, prompt, parasocial, and situationship.
After a four-day voting period, the public chose their four favourite words of the year: rizz, Swiftie, prompt, and situationship. These words were then evaluated by Oxford&rsquo;s language experts to choose the definitive word of the year for 2023, and they chose rizz!
Also watch: <a href="https://www.editorji.com/world-news/ai-has-been-named-word-of-the-year-by-collins-dictionary-1698813065118">'AI' has been named word of the year by Collins Dictionary</a>

Scientists at the University of Oxford have identified a gene that may double the risks of lung failure and death from COVID-19, and could explain why people of South Asian ancestry have a higher risk of severe disease.
The LZTFL1 gene changes the way the lungs respond to viral infection, and is the most important genetic risk factor identified so far, the researchers said.
They noted that the gene version is carried by nearly 60 per cent of people with South Asian background, compared with 15 per cent of those with European lineage.
The finding, published in the journal Nature Genetics on Thursday, could also partly explain the impact of COVID-19 in the Indian subcontinent.
The researchers used a combination of artificial intelligence (AI) and new molecular technology to pinpoint LZTFL1 as a gene responsible for the increased risks.
LZTFL1 blocks a key protective mechanism that cells lining the lungs normally use to defend themselves from the viral infection, they said.
When these cells interact with SARS-CoV-2, which causes COVID-19, one of their defence strategies is to turn into less specialised cells and become less welcoming to the virus.
This process reduces the amount on the surface of cells of a key protein called ACE2, which the coronavirus uses to attach itself to the cells.
However, for people with the LZTFL1 gene this process does not work as well, and lung cells are left vulnerable to infection by the virus.
The researchers noted that it is particularly important to offer vaccination to communities that are at greater risk of serious COVID-19 infection as a consequence of carrying this genetic predisposition, as their increased risk should be cancelled out by immunisation.
Independent experts said the findings are very important but warrant further investigation.
&ldquo;The discrepancy between the risk of serious disease and death in different ethnic groups has previously been attributed in part to socio-economic&nbsp;differences, but it was clear that this was not a complete explanation," said Professor Frances Flinter, from Guy&rsquo;s &amp; St Thomas&rsquo; NHS Foundation Trust, UK.
&ldquo;Evidence that LZTFL1 has emerged as a candidate causal gene, which is potentially responsible for some of the two-fold increased risk of respiratory failure from COVID-19 in some populations, provides a big step forward in our understanding of the variable susceptibility&nbsp;of some individuals to serious disease and death,&rdquo; Flinter, who was not involved in the study, added.
Simon Biddie, from the University of Edinburgh, UK, said the study provides compelling evidence to suggest roles for LZFTL1 in severe COVID-19 that warrants urgent further investigation.
&ldquo;The finding will need further experimental verification to provide direct evidence for regulation of LZTFL1, using for example genome engineering approaches," Biddie, who was not a part of the study, added.

Oxford-led study: gene common in South Asians may double risk of Covid-19 death

Oxford-led study: gene common in South Asians may double risk of Covid-19 death. Here is more.

Scientists at the University of Oxford have identified a gene that may double the risks of lung failure and death from COVID-19 and could explain why people of South Asian ancestry have a higher risk of severe disease.
The LZTFL1 gene changes the way the lungs respond to viral infection and is the most important genetic risk factor identified so far, the researchers said.
They noted that the gene version is carried by nearly 60 per cent of people with South Asian background, compared with 15 per cent of those with European lineage.
The finding, published in the journal Nature Genetics on Thursday, could also partly explain the impact of COVID-19 in the Indian subcontinent.
The researchers used a combination of artificial intelligence and new molecular technology to pinpoint LZTFL1 as a gene responsible for the increased risks.
LZTFL1 blocks a key protective mechanism that cells lining the lungs normally use to defend themselves from the viral infection, they said.
When these cells interact with SARS-CoV-2, which causes COVID-19, one of their defence strategies is to turn into less specialised cells and become less welcoming to the virus.
This process reduces the amount on the surface of cells of a key protein called ACE2, which the coronavirus uses to attach itself to the cells.
However, for people with the LZTFL1 gene, this process does not work as well, and lung cells are left vulnerable to infection by the virus.
Independent experts said the findings are very important but warrant further investigation.
&nbsp;

The LZTFL1 gene changes the way the lungs respond to viral infection and is the most important genetic risk factor identified so far, the researchers said

Scientists at the University of Oxford have identified a gene that may double the risks of lung failure and death from COVID-19, and could explain why people of South Asian ancestry have a higher risk of severe disease.
The LZTFL1 gene changes the way the lungs respond to viral infection and is the most important genetic risk factor identified so far, the researchers said.
They noted that the gene version is carried by nearly 60 per cent of people with South Asian background, compared with 15 per cent of those with European lineage.
Also watch |&nbsp;<a href="https://www.editorji.com/india-news/coronavirus-how-do-covid-19-boosters-work-and-are-they-same-as-the-original-vaccines-1636079209378" target="_blank">Coronavirus: How do Covid-19 boosters work and are they same as the original vaccines?</a>
The finding, published in the journal Nature Genetics on Thursday, could also partly explain the impact of COVID-19 in the Indian subcontinent.
The researchers used a combination of artificial intelligence (AI) and new molecular technology to pinpoint LZTFL1 as a gene responsible for the increased risks.
LZTFL1 blocks a key protective mechanism that cells lining the lungs normally use to defend themselves from the viral infection, they said.
When these cells interact with SARS-CoV-2, which causes COVID-19, one of their defence strategies is to turn into less specialised cells and become less welcoming to the virus.
This process reduces the amount on the surface of cells of a key protein called ACE2, which the coronavirus uses to attach itself to the cells.
However, for people with the LZTFL1 gene this process does not work as well, and lung cells are left vulnerable to infection by the virus.
The researchers noted that it is particularly important to offer vaccination to communities that are at greater risk of serious COVID-19 infection as a consequence of carrying this genetic predisposition, as their increased risk should be cancelled out by immunisation.
Independent experts said the findings are very important but warrant further investigation.
&ldquo;The discrepancy between the risk of serious disease and death in different ethnic groups has previously been attributed in part to socio-economic&nbsp;differences, but it was clear that this was not a complete explanation," said Professor Frances Flinter, from Guy&rsquo;s &amp; St Thomas&rsquo; NHS Foundation Trust, UK.
&ldquo;Evidence that LZTFL1 has emerged as a candidate causal gene, which is potentially responsible for some of the two-fold increased risk of respiratory failure from COVID-19 in some populations, provides a big step forward in our understanding of the variable susceptibility&nbsp;of some individuals to serious disease and death,&rdquo; Flinter, who was not involved in the study, added.
Simon Biddie, from the University of Edinburgh, UK, said the study provides compelling evidence to suggest roles for LZFTL1 in severe COVID-19 that warrants urgent further investigation.
&ldquo;The finding will need further experimental verification to provide direct evidence for regulation of LZTFL1, using for example genome engineering approaches," Biddie, who was not a part of the study, added.

Possibly settling the debate once and for all, a large Oxford study has found that there is no 'safe amount' when it comes to drinking alcohol.
The observational study of over 25,000 people, which is still to be peer-reviewed, found that alcohol consumption has an impact on the brain's grey matter, the parts where information is processed. The more alcohol you consume, the lower your brain&nbsp;volume, remarked the lead researcher.
Adding to a growing body of evidence stacked against booze, the findings confirm that 'there&rsquo;s no threshold drinking for harm &ndash; any alcohol is worse.'&nbsp;
In fact, the type of alcohol including wine, spirits or beers did not make a difference, meaning that no drink is better or worse than the other.
However, certain characteristics, such as high blood pressure, obesity or binge drinking, could put people at higher risk, researchers added.
It is important to note that while alcohol made a small contribution to this (0.8%) decline in brain volume, it was also a greater contribution than other 'modifiable' risk factors.

No amount of alcohol is ‘safe’ for consumption, finds Oxford study

No amount of alcohol is safe for consumption: Oxford study
Study of 25,000 British adults; yet to be peer-reviewed&nbsp;
The more alcohol consumed, the lower the brain volume
Adds to the growing body of evidence against alcohol
Wine or beer?&nbsp;The type of alcohol made no difference
Conditions like high BP or obesity could increase the risk
Alcohol the greatest contributor amongst 'modifiable' risk factors

Adding to a growing body of evidence stacked against booze, the findings confirm that 'there&rsquo;s no threshold drinking for harm &ndash; any alcohol is worse.'&nbsp;

Possibly settling the debate once and for all, a large Oxford study has found that there is no 'safe amount' when it comes to drinking alcohol.
The observational study of over 25,000 people, which is still to be peer-reviewed, found that alcohol consumption has an impact on the brain's grey matter, the parts where information is processed. The more alcohol you consume, the lower your brain&nbsp;volume, remarked the lead researcher.
Adding to a growing body of evidence stacked against booze, the findings confirm that 'there&rsquo;s no threshold drinking for harm &ndash; any alcohol is worse.'&nbsp;
In fact, the type of alcohol including wine, spirits or beers did not make a difference, meaning that no drink is better or worse than the other.
However, certain characteristics, such as high blood pressure, obesity or binge drinking, could put people at higher risk, researchers added.
It is important to note that while alcohol made a small contribution to this (0.8%) decline in brain volume, it was also a greater contribution than other 'modifiable' risk factors.

Foreign Minister S Jaishankar said that India is land of Mahatama Gandhi and it can never turn its eyes away from racism.

Oxford University Racism Row: India will take up with UK racism issues when required, says EAM S Jaishankar

India will take up with the UK the alleged incidents of racism in Britain when required, External Affairs Minister S Jaishankar said in the Rajya Sabha on Monday. Responding to concerns raised by a BJP MP over racism and cyberbullying that forced Indian-origin Rashmi Samant to resign as president of the Oxford University Students Union, the minister said New Delhi has strong ties with the UK and will take up such matters with great candour. Describing India as the land of Mahatma Gandhi, the minister said the country can never turn its eyes away from racism.

EAM Jaishankar: India will take up with UK racism issues when required

EAM&nbsp;addresses Oxford racism row in Rajya&nbsp;Sabha
Govt: India will take up racism&nbsp;issue with UK when required
Oxford racism row: cyberbulling&nbsp;of India's&nbsp;Rashmi&nbsp;Samant&nbsp;
Samant&nbsp;had to resign from&nbsp;Oxford University Students Union
Jaishankar: India will not turn its eyes away from racism

The government on Monday assured the Rajya Sabha that it will raise the issue of alleged incident of racism and cyberbullying with Indian origin student at Oxford University, with the UK when required.
Foreign Minister S Jaishankar said that India is land of Mahatama Gandhi and it can never turn its eyes away from racism.
Rashmi Samant, who was the first Indian woman to become the president of the Oxford University Students Union, resigned in February after a controversy erupted over her remarks on social media which were labelled as anti-Semitic and racist.

Boosting hope, study finds Oxford virus vaccine builds strong immunity

Bristol University study has found that the Oxford&nbsp;Covid-19 vaccine builds strong immunity to the virus.&nbsp;

Oxford coronavirus vaccine builds strong immunity, study finds

Study: Oxford vaccine builds strong immunity to Covid-19 New study on Oxford vaccine&nbsp;boosts global vaccination hope&nbsp; Vaccine front runner&nbsp;has entered Phase III clinical trials Study confirms vaccine successful in creating spike protein&nbsp; Vaccine induces strong immune response, study suggests

In a boost to global coronavirus vaccination hopes, a study has found that the Covid-19 vaccine spearheaded by Oxford University builds strong immunity to the virus. As the front-runner in the global race for a vaccine entered final Phase III clinical trials, researchers at Bristol University carried out tests to check whether it was behaving as intended. The Bristol team found that the vaccine was successfully able to instruct human cells to copy the genetic instructions to create the spike protein. The study confirmed that large amounts of the coronavirus spike protein are produced with great accuracy, and this goes a long way to explaining the success of the vaccine in inducing a strong immune response. Sarah Gilbert, who leads the Oxford University vaccine trial, praised the study for helping to explain the vaccine&rsquo;s effectiveness.

Brazil: Oxford Covid vaccine trial volunteer dies 

Brazilian health authority said on Wednesday that a volunteer in a clinical trial of the Covid-19 vaccine developed by AstraZeneca and Oxford University has died

Brazilian health authority said on Wednesday that a volunteer in a clinical trial of the Covid-19 vaccine developed by AstraZeneca and Oxford University has died, news agency Reuters has reported. The regulator said testing of the vaccine would continue after the volunteer's death. It provided no further details, citing medical confidentiality of those involved in trials, the report added. The Federal University of Sao Paulo, which is helping coordinate phase 3 clinical trials in Brazil, separately said that the volunteer was Brazilian but did not say where the person lived.

Thailand to make, supply AstraZeneca's Covid-19 vaccine

Thailand has agreed to manufacture and supply AstraZeneca experimental Covid-19 vaccine in the southeast Asian country and other nations in the region

Thailand has agreed to manufacture and supply AstraZeneca experimental Covid-19 vaccine in the southeast Asian country and other nations in the region, the British and Thai governments said on Monday. The announcement by the British embassy in Bangkok did not specify how many doses of the vaccine candidate would be distributed in Thailand. It also did not disclose the financial terms of the deal. AstraZeneca is developing a Covid vaccine alongwith the Oxford University.

Oxford University: Covid vaccine candidate trial will resume

Oxford University says trials of a coronavirus vaccine that it is developing with pharmaceutical company AstraZeneca will resume, days after being paused due to a reported side-effect in a patient in the UK.
In a statement, the university said in large trials such as this &ldquo;it is expected that some participants will become unwell and every case must be carefully evaluated to ensure careful assessment of safety.&rdquo; It said that globally some 18,000 people have received the vaccine as part of the trial.
It would not disclose information about the patient's illness for reasons of participant confidentiality but insisted that it is &ldquo;committed to the safety of our participants and the highest standards of conduct in our studies and will continue to monitor safety closely.&rdquo; Pauses in drug trials are commonplace.&nbsp;

Oxford University says trials of a coronavirus vaccine that it is developing with pharmaceutical company AstraZeneca will resume, days after being paused due to a reported side-effect in a patient in the UK. In a statement, the university said in large trials such as this &ldquo;it is expected that some participants will become unwell and every case must be carefully evaluated to ensure careful assessment of safety.&rdquo; It said that globally some 18,000 people have received the vaccine as part of the trial. The varsity&nbsp;would not disclose information about the patient's illness for reasons of participant confidentiality but insisted that it is &ldquo;committed to the safety of our participants and the highest standards. Pauses in drug trials are commonplace.&nbsp;

Oxford University says trials of a coronavirus vaccine that it is developing with pharmaceutical company AstraZeneca will resume, days after being paused due to a reported side-effect in a patient in the UK.
In a statement, the university said in large trials such as this &ldquo;it is expected that some participants will become unwell and every case must be carefully evaluated to ensure careful assessment of safety.&rdquo; It said that globally some 18,000 people have received the vaccine as part of the trial.
It would not disclose information about the patient's illness for reasons of participant confidentiality but insisted that it is &ldquo;committed to the safety of our participants and the highest standards of conduct in our studies and will continue to monitor safety closely.&rdquo; Pauses in drug trials are commonplace.&nbsp;

Contact tracing apps can reduce Covid spread: study

Contact tracing apps can sharply reduce the spread of the novel coronavirus even when only a few people use them, a study by Google and Oxford University has said

Contact tracing apps can sharply reduce the spread of the novel coronavirus even when only a few people use them, a study published on Thursday by researchers at Google and Oxford University showed. An app used by 15% of the population together with a well-staffed contact-tracing workforce can lead to a 15% drop in infection rates and an 11% drop in Covid-19 deaths, says the study.

oxford university

Categories